Hyderabad-based biotechnology company Bharat Biotech has announced ‘COVAXIN‘ as Indian’s first COVID-19 vaccine candidate. The new vaccine is approved by the Drug Controller General of India (DCGI). The company will soon start Phase I and II of human clinical trials around the country. COVAXIN has been developed and manufactured at the company’s Bio-safety Level-III high containment facility in Genome Valley, Hyderabad. The human clinical trials will begin in India from July and results are expected to deliver by October this year. The new COVAXIN is an inactivated vaccine that has been developed after the National Institute of Virology (NIV) Pune isolated the strain of coronavirus i.e. ‘SARS-CoV-2’.